If you have ever wondered what a kidney disease trial is actually trying to prove, IgA nephropathy is a clean place to start. The disease is caused by clumps of an antibody called IgA that build up in the kidney's tiny filters, triggering inflammation and slow scarring. The damage shows up early as protein leaking into the urine — a sign the filters are no longer sealing properly. So when Biogen designed its new Phase 3 trial, called PREVAIL and registered as NCT06935357, it built the whole study around that one measurable leak.
The drug being tested is felzartamab, an antibody therapy with a different strategy from the steroids and blood-pressure drugs that have long anchored IgA nephropathy care. Instead of broadly calming inflammation, felzartamab is aimed upstream, at the immune cells that manufacture the faulty antibodies in the first place. The logic is that if you shut down the factory, you stop making the clumps that gum up the kidney. ClinicalTrials.gov, the U.S. National Library of Medicine registry where the protocol is posted, describes the rationale plainly.
"IgAN is a kidney disease caused by the buildup of an antibody called IgA in the kidneys over time. In people with IgAN, abnormal IgA and other antibodies form clusters that build up in the small filters of the kidneys, which leads to inflammation and damage."— ClinicalTrials.gov, source
Here is what the trial is built to answer. It is randomized, double-blind, and placebo-controlled, the gold-standard design where neither patients nor their doctors know who is getting the real drug. The plan is to enroll an estimated 454 adults, sponsored by Biogen, and randomize them to receive either felzartamab or a matching placebo on top of their existing care. The single primary outcome is the percent change from baseline in proteinuria, measured by the urine protein-to-creatinine ratio, or UPCR, at Week 36. In plain terms: does the drug shrink the leak, and by how much, after about eight months?
Why proteinuria is the metric that matters
Proteinuria sounds like a lab curiosity, but in kidney disease it is one of the most reliable early warning lights on the dashboard. The amount of protein spilling into the urine tracks closely with how fast a kidney is heading toward failure, which is why regulators have increasingly accepted a reduction in proteinuria as a meaningful signal in IgA nephropathy trials. It lets a study read out in months rather than the many years it would take to watch kidneys actually fail. That is the practical reason PREVAIL anchors its primary endpoint on a UPCR change at Week 36 rather than waiting for dialysis-level events.
The protocol does not stop at that first measurement. Biogen's detailed description lays out a tiered set of objectives: the primary one on proteinuria, a main secondary objective on the kidney's filtering ability, and additional secondary objectives covering other clinical endpoints plus the drug's pharmacokinetics and immunogenicity — how it moves through the body and whether the immune system starts treating the antibody itself as a foreign target. That layered structure is typical of a modern Phase 3: prove the headline benefit first, then assemble the supporting evidence regulators will want before an approval.
What recruiting status tells you, and what it doesn't
As of its latest update on the registry, PREVAIL is listed as recruiting, with a start date in May 2025. Recruiting is exactly what it sounds like — the trial is open and enrolling — and it is worth being clear about what that status does and does not mean. It does not mean felzartamab works in IgA nephropathy; that is the entire question the trial exists to settle. It does not mean an approval is near. It means Biogen has cleared the regulatory and ethical reviews needed to begin dosing patients and is now assembling the cohort that will generate the data.
For readers tracking the broader nephrology landscape, the felzartamab program sits inside a busy moment for IgA nephropathy. After decades in which the disease had little beyond supportive care, a cluster of mechanisms — complement inhibitors, endothelin antagonists, and B-cell or plasma-cell-directed antibodies like this one — are now being tested head-to-head against placebo on proteinuria endpoints. The competitive question is not just whether a drug lowers protein, but by how much, how durably, and with what safety profile over the long haul. PREVAIL's design, with its pharmacokinetic and immunogenicity sub-studies, is positioned to gather exactly those comparison points.
The short version is this: felzartamab is being asked to do one concrete thing first — reduce the protein leaking from damaged kidneys by Week 36 — and the rest of the program is built to find out whether that early signal translates into preserved kidney function over time. Until the data read out, the registry entry is a statement of intent, not of outcome. But it is a transparent one, and the primary endpoint is specific enough that, when results arrive, there will be little room to spin them. That clarity is the whole point of registering a trial before you run it.
Patients and clinicians who want to follow the study can track its status, enrollment, and any posted results directly on the ClinicalTrials.gov record, which the sponsor is obligated to keep current. For a disease where the treatment menu was thin for so long, even a well-defined question being asked rigorously counts as progress.